Genentech Releases SMA Community Letter

Genentech, a member of the Roche Group, logo

Genentech recently issued an SMA community statement highlighting updates from the 2023 SMA Research & Clinical Care Meeting.

These updates included:

  • Investigating risdiplam treatment post gene-therapy
  • Long-term efficacy and safety of risdiplam
  • Real-world evidence generation

Check out the full community statement here.

Do you like what you're reading?

Help make a difference in the lives of people affected by spinal muscular atrophy.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top